Company Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Stockholm Other stock markets 08:43:08 26/04/2024 pm IST			5-day change	1st Jan Change
40.45 ^SEK	+0.50%		+2.53%	+1.12%

14/02	Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
12/02	US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment	MT

XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.

Number of employees: 26

Managers	Title	Age	Since
Per Andersson CEO	Chief Executive Officer	57	01/06/01
Michael af Winklerfelt DFI	Director of Finance/CFO	52	08/02
Thomas Walz CTO	Chief Tech/Sci/R&D Officer	-	01/22/01
Charlotta Liljebris CTO	Chief Tech/Sci/R&D Officer	60	01/18/01
Kerstin Hasselgren IRC	Investor Relations Contact	63	15/19/15
Anna-Karin Ekberg SAM	Sales & Marketing	-	15/22/15
Andreas Konar PRN	Corporate Officer/Principal	75	01/10/01
Edward Jordan PRN	Corporate Officer/Principal	55	15/23/15

Members of the board	Title	Age	Since
Maris Gunars Hartmanis BRD	Director/Board Member	71	01/15/01
Carl-Johan Spak BRD	Director/Board Member	68	01/15/01
Anders Olof Adolf Ekblom CHM	Chairman	70	19/22/19
Torbjörn Mattias Koivisto BRD	Director/Board Member	55	01/17/01
Christine Lind BRD	Director/Board Member	50	01/19/01
Anders Lennart Bladh BRD	Director/Board Member	66	01/21/01
Robert Molander BRD	Director/Board Member	59	19/22/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	31,253,542	16,001,596 ( 51.20 %)	0	51.20 %

Name	Equities	%	Valuation
Anders Lennart Bladh 12.89 %	4,027,091	12.89 %	16 M kr
Flerie Invest AB 11.08 %	3,464,378	11.08 %	14 M kr
Östersjöstiftelsen (Private Equity) 8.775 %	2,742,626	8.775 %	11 M kr
Fjärde AP-fonden 6.386 %	1,995,806	6.386 %	8 M kr
Teknik Innovation Norden Fonder AB 2.698 %	843,210	2.698 %	3 M kr
Unionen 2.579 %	806,000	2.579 %	3 M kr
Tredje AP-fonden 2.560 %	800,000	2.560 %	3 M kr
Andra AP-fonden 1.991 %	622,320	1.991 %	2 M kr
Per Andersson 0.7753 %	242,294	0.7753 %	953 984 kr
C Worldwide Asset Management Fondsmæglerselskab A/S (Sweden) 0.7398 %	231,200	0.7398 %	910 304 kr

Xspray Pharma AB

Råsundavägen 12

169 67, Solna

+46 87 30 37 00

http://www.xspraypharma.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.45 SEK

Average target price

107 SEK

Spread / Average Target

+164.52%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
XSPRAY PHARMA AB	+1.12%	115M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs